AAPL   383.32 (+0.15%)
MSFT   213.20 (-0.52%)
FB   244.87 (+0.15%)
GOOGL   1,532.27 (+0.90%)
AMZN   3,200.87 (+0.57%)
NVDA   418.92 (-0.34%)
BABA   261.40 (-0.07%)
TSLA   1,532.47 (+9.91%)
AMD   55.90 (-2.38%)
T   30.10 (+1.90%)
ACB   11.92 (+1.27%)
F   6.07 (+3.76%)
GILD   76.31 (+2.14%)
DIS   119.19 (+2.03%)
NFLX   548.12 (+7.95%)
BA   177.87 (+2.65%)
AAPL   383.32 (+0.15%)
MSFT   213.20 (-0.52%)
FB   244.87 (+0.15%)
GOOGL   1,532.27 (+0.90%)
AMZN   3,200.87 (+0.57%)
NVDA   418.92 (-0.34%)
BABA   261.40 (-0.07%)
TSLA   1,532.47 (+9.91%)
AMD   55.90 (-2.38%)
T   30.10 (+1.90%)
ACB   11.92 (+1.27%)
F   6.07 (+3.76%)
GILD   76.31 (+2.14%)
DIS   119.19 (+2.03%)
NFLX   548.12 (+7.95%)
BA   177.87 (+2.65%)
AAPL   383.32 (+0.15%)
MSFT   213.20 (-0.52%)
FB   244.87 (+0.15%)
GOOGL   1,532.27 (+0.90%)
AMZN   3,200.87 (+0.57%)
NVDA   418.92 (-0.34%)
BABA   261.40 (-0.07%)
TSLA   1,532.47 (+9.91%)
AMD   55.90 (-2.38%)
T   30.10 (+1.90%)
ACB   11.92 (+1.27%)
F   6.07 (+3.76%)
GILD   76.31 (+2.14%)
DIS   119.19 (+2.03%)
NFLX   548.12 (+7.95%)
BA   177.87 (+2.65%)
AAPL   383.32 (+0.15%)
MSFT   213.20 (-0.52%)
FB   244.87 (+0.15%)
GOOGL   1,532.27 (+0.90%)
AMZN   3,200.87 (+0.57%)
NVDA   418.92 (-0.34%)
BABA   261.40 (-0.07%)
TSLA   1,532.47 (+9.91%)
AMD   55.90 (-2.38%)
T   30.10 (+1.90%)
ACB   11.92 (+1.27%)
F   6.07 (+3.76%)
GILD   76.31 (+2.14%)
DIS   119.19 (+2.03%)
NFLX   548.12 (+7.95%)
BA   177.87 (+2.65%)
Log in

NASDAQ:BPMCBlueprint Medicines Stock Price, Forecast & News

$79.38
+1.00 (+1.28 %)
(As of 07/10/2020 03:44 PM ET)
Add
Compare
Today's Range
$78.23
Now: $79.38
$79.86
50-Day Range
$63.49
MA: $72.77
$79.32
52-Week Range
$43.29
Now: $79.38
$102.98
Volume7,977 shs
Average Volume428,703 shs
Market Capitalization$4.30 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.09
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, an inhibitor targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Read More
Blueprint Medicines logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.62 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BPMC
CUSIPN/A
Phone617-374-7580

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$66.51 million
Book Value$9.44 per share

Profitability

Net Income$-347,690,000.00
Net Margins-515.98%

Miscellaneous

Employees217
Market Cap$4.30 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive BPMC News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.

Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions

How has Blueprint Medicines' stock been impacted by COVID-19 (Coronavirus)?

Blueprint Medicines' stock was trading at $52.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BPMC stock has increased by 50.8% and is now trading at $79.03. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Blueprint Medicines?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Blueprint Medicines.

When is Blueprint Medicines' next earnings date?

Blueprint Medicines is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Blueprint Medicines.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Corp (NASDAQ:BPMC) announced its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($2.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.08) by $0.03. The biotechnology company had revenue of $6.20 million for the quarter, compared to analysts' expectations of $5.57 million. Blueprint Medicines had a negative net margin of 515.98% and a negative return on equity of 65.81%. The firm's revenue for the quarter was up 749.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.98) earnings per share. View Blueprint Medicines' earnings history.

What price target have analysts set for BPMC?

13 brokerages have issued 1-year target prices for Blueprint Medicines' shares. Their forecasts range from $59.00 to $122.00. On average, they expect Blueprint Medicines' stock price to reach $95.67 in the next year. This suggests a possible upside of 21.1% from the stock's current price. View analysts' price targets for Blueprint Medicines.

Has Blueprint Medicines been receiving favorable news coverage?

Headlines about BPMC stock have been trending somewhat positive recently, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Blueprint Medicines earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Blueprint Medicines.

Who are some of Blueprint Medicines' key competitors?

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), Micron Technology (MU), AbbVie (ABBV), Crispr Therapeutics (CRSP), Amarin (AMRN), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Nektar Therapeutics (NKTR), Alibaba Group (BABA) and Gilead Sciences (GILD).

Who are Blueprint Medicines' key executives?

Blueprint Medicines' management team includes the following people:
  • Mr. Jeffrey W. Albers, CEO, Pres & Director (Age 48)
  • Mr. Alexis A. Borisy, Co-Founder & Director (Age 47)
  • Mr. Michael Landsittel, Chief Financial Officer (Age 47)
  • Ms. Kathryn Haviland, Chief Operating Officer (Age 43)
  • Dr. Christopher K. Murray, Sr. VP of Technical Operations (Age 56)

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.03%) and Nelson Van Denburg & Campbell Wealth Management Group LLC (0.01%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Debra Durso-Bumpus, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View institutional ownership trends for Blueprint Medicines.

Which major investors are buying Blueprint Medicines stock?

BPMC stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., and Nelson Van Denburg & Campbell Wealth Management Group LLC. View insider buying and selling activity for Blueprint Medicines.

How do I buy shares of Blueprint Medicines?

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $79.03.

How big of a company is Blueprint Medicines?

Blueprint Medicines has a market capitalization of $4.28 billion and generates $66.51 million in revenue each year. The biotechnology company earns $-347,690,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis. Blueprint Medicines employs 217 workers across the globe.

What is Blueprint Medicines' official website?

The official website for Blueprint Medicines is www.blueprintmedicines.com.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.